HC Wainwright Rates Tango Therapeutics (TNGX) buy

HC Wainwright has reaffirmed its buy rating on Tango Therapeutics, Inc., maintaining a $66.00 price target for the clinical-stage biotechnology company, a 113.32% upside from the current price.

By EarningsIQ Research Desk · Published Jun 13, 2026, 2:09 AM EDT · Updated Jun 15, 2026, 9:01 AM EDT

Reviewed by automated data checks against the source data. How we make and check alerts

HC Wainwright rated Tango Therapeutics, Inc. ($TNGX) "buy" with a $66 price target on June 9, 2026.

Since the rating, $TNGX is up 1.9% after 1 week, down 3.3% after 1 month and down 30.2% to date (from the $31.56 close on Jun 9, 2026).

TNGX Tango Therapeutics, Inc.

$22.04 +146.81% year to date

Daily close · Oct 16, 2026

Key Points

HC Wainwright analyst Robert Burns reiterated a buy rating on Tango Therapeutics, Inc. (NasdaqGM: TNGX) with a price target of $66.00 on June 9, 2026.
HC Wainwright's $66 price target implies 113.32% upside from Tango Therapeutics, Inc.'s ($TNGX) current $30.94 share price.
Tango Therapeutics stock trades near $30.94, well above its 200-day moving average of $20.27 and close to its 52-week high of $34.39.
The broader analyst community holds a strong buy consensus on the stock, with a mean price target of $45.18 across 11 opinions.

Get $TNGX trade alerts by text

We text you when insiders, Congress or big funds trade $TNGX. Free.

Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Tango Therapeutics, Inc. alert may contain errors. Disclosures

HC Wainwright Reaffirms Outlook on Tango Therapeutics

HC Wainwright analyst Robert Burns reiterated a buy rating on Tango Therapeutics, Inc. (NasdaqGM: TNGX) on June 9, 2026, keeping a price target of $66.00 on the precision oncology company. The firm's ongoing support reflects confidence in the biotechnology developer's clinical pipeline and targeted cancer therapies.

Tango Therapeutics Stock Trades Near Highs

Tango Therapeutics shares recently changed hands at $30.94, sitting comfortably above the 50-day moving average of $25.64 and the 200-day moving average of $20.27. The stock has experienced strong upward momentum, trading close to its 52-week high of $34.39 while remaining well clear of its 52-week low of $6.69.

12-month forecast

$TNGX price target

Tango Therapeutics, Inc. daily closes and this analyst's $66 target. Not advice.

Analysts Set New Price Targets

Wall Street firms continue to monitor the company closely as clinical trials progress. On August 18, 2026, HC Wainwright & Co. maintained a buy rating and raised its price target to $68.00. Guggenheim maintained a buy rating with a $35.00 target on August 12, 2026, while Mizuho maintained an outperform rating with a $40.00 target on July 17, 2026. JP Morgan initiated coverage with an overweight rating and a $46.00 target on July 15, 2026. Canaccord Genuity maintained a buy rating with a $46.00 target on June 29, 2026, and Jefferies upgraded the stock to a buy with a $60.00 target on June 26, 2026. William Blair also initiated coverage with an outperform rating on October 16, 2026. Overall, the stock carries a strong buy recommendation key from a total of 11 analyst opinions, with a mean price target of $45.18.

Focused on Precision Oncology

Tango Therapeutics, Inc. is a Boston-based biotechnology company focused on discovering and developing precision medicines for defined patient populations with high unmet medical needs. The company works on novel drug candidates such as PRMT5 inhibitors for treating pancreatic and lung cancers, aiming to overcome resistance mechanisms found in various tumors. This clinical pipeline serves as the primary driver behind analyst evaluations and long-term valuation targets.

What to Watch at Tango Therapeutics, Inc.

Investors will look toward the company's next scheduled financial results and pipeline updates, with the upcoming earnings report expected around November 4, 2026. Analyst targets and rating adjustments will continue to guide market sentiment as clinical data readouts approach. As always, analyst ratings represent individual firm opinions and do not constitute financial advice.